黄蜀葵花制剂联合指南导向药物治疗心肌梗死后心力衰竭临床研究OA
Clinical research on Abelmoschus manihot combined with guideline-directed medical therapy in post-myocardial infarction heart failure
目的:观察黄蜀葵花制剂(甲花片)联合指南导向药物治疗(GDMT)心肌梗死(MI)后心力衰竭(HF)患者的临床疗效.方法:研究选取心肌梗死后心力衰竭的 65 例患者,将患者采用随机数字表法分为观察组 30 例及对照组 35 例.对照组给予 GDMT;观察组在 GDMT 基础上联合甲花片治疗.观察比较两组治疗前及治疗后第 7 天的中医证候积分、血清 N 末端 B 型脑钠肽前体(NT-proBNP)、心肌肌钙蛋白 I(cTnI)、可溶性生长刺激表达基因 2 蛋白(sST2)、白细胞介素-6(IL-6)及总超氧化物歧化酶(T-SOD)水平,评估其临床疗效.结果:治疗后,观察组患者的中医证候积分及血清 NT-proBNP、cTnI、IL-6 水平均较治疗前显著降低(P<0.01),血清 T-SOD 水平较治疗前显著升高(P<0.01),而对照组上述指标治疗前后差异均无统计学意义(P>0.05).在血清 sST2 水平方面,观察组治疗前后保持稳定(P>0.05),对照组则较治疗前显著升高(P<0.05).组间比较显示,治疗后观察组各项指标或控制水平显著优于对照组(P<0.05).结论:在 GDMT 基础上,联合使用甲花片可显著改善心梗后心衰患者的中医证候,减轻心肌损伤、抑制急性期 sST2 及炎症因子水平,增强抗氧化能力,对改善早期心室重构相关的微环境有积极意义.
Objective:To observe clinical efficacy of the combination of Abelmoschus manihot preparation(Ji-ahua tablets)and guideline-directed medical therapy(GDMT)in patients with heart failure(HF)after myocardial infarction(MI).Methods:A total of 65 patients with heart failure after myocardial infarction were selected for the study and randomly divided into an observation group(30 cases)and a control group(35 cases)using a random number table.The control group was treated with GDMT,while the observation group was treated with Jiahua tab-lets in addition to GDMT.The TCM syndrome scores,serum N-terminal pro-B-type natriuretic peptide(NT-proB-NP),cardiac troponin I(cTnI),soluble suppression of tumorigenicity 2(sST2),interleukin-6(IL-6),and total su-peroxide dismutase(T-SOD)levels were observed and compared before and 7 days after treatment in both groups to evaluate the clinical efficacy.Results:After treatment,the TCM syndrome scores and serum NT-proBNP,cTnI,and IL-6 levels in the observation group were significantly lower than those before treatment(P<0.01),and the serum T-SOD level was significantly higher than that before treatment(P<0.01).However,there were no statistically significant differences in the above indicators before and after treatment in the control group(P>0.05).Regarding the serum sST2 level,it remained stable in the observation group before and after treatment(P>0.05),while it was significantly higher in the control group after treatment compared with before treatment(P<0.05).Inter-group comparison showed that the observation group had significantly better control of all indicators after treatment than the control group(P<0.05).Conclusion:In addition to GDMT,the combination of Jiahua Tablets can significantly improve the TCM syndrome of patients with heart failure after myocardial infarction,reduce myocardial injury,inhib-it the levels of sST2 and inflammatory factors in the acute phase,enhance antioxidant capacity,and has positive sig-nificance in improving microenvironment related to early ventricular remodeling.
王小龙;贾琪;林欣;牛茹歌;杨文莉;包桐;王令谆
南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029南京中医药大学附属医院,江苏 南京 210029
医药卫生
心肌梗死后心力衰竭黄蜀葵花甲花片可溶性生长刺激表达基因 2 蛋白心室重构炎症因子
Post-myocardial infarction heart failureAbelmoschus manihotJiahua tabletsSoluble suppres-sion of tumorigenicity 2Ventricular remodelingInflammatory factor
《陕西中医》 2026 (5)
635-640,646,7
江苏省中医药科技发展计划项目(YB2020007)江苏省中医临床医学创新中心项目(苏中医科技函[2023]1号)
评论